Log in

NASDAQ:CBLICleveland BioLabs Stock Price, Forecast & News

$2.05
+0.09 (+4.59 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.95
Now: $2.05
$2.05
50-Day Range
$1.57
MA: $1.80
$2.27
52-Week Range
$0.50
Now: $2.05
$5.00
Volume39,163 shs
Average Volume188,723 shs
Market Capitalization$23.37 million
P/E RatioN/A
Dividend YieldN/A
Beta0.78
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Read More
Cleveland BioLabs logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBLI
CUSIPN/A
Phone716-849-6810

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.11 million
Book Value$0.07 per share

Profitability

Net Income$-2,650,000.00
Net Margins-220.62%

Miscellaneous

EmployeesN/A
Market Cap$23.37 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

How has Cleveland BioLabs' stock been impacted by COVID-19 (Coronavirus)?

Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CBLI shares have decreased by 34.9% and is now trading at $2.05. View which stocks have been most impacted by Coronavirus.

When is Cleveland BioLabs' next earnings date?

Cleveland BioLabs is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Cleveland BioLabs.

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced its earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) EPS for the quarter. The biotechnology company earned $0.16 million during the quarter. Cleveland BioLabs had a negative return on equity of 169.32% and a negative net margin of 220.62%. View Cleveland BioLabs' earnings history.

Has Cleveland BioLabs been receiving favorable news coverage?

News headlines about CBLI stock have been trending very negative on Sunday, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cleveland BioLabs earned a news impact score of -3.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutCleveland BioLabs.

Are investors shorting Cleveland BioLabs?

Cleveland BioLabs saw a decrease in short interest in May. As of May 15th, there was short interest totaling 53,000 shares, a decrease of 30.4% from the April 30th total of 76,100 shares. Based on an average daily trading volume, of 511,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.3% of the shares of the company are short sold. View Cleveland BioLabs' Current Options Chain.

Who are some of Cleveland BioLabs' key competitors?

What other stocks do shareholders of Cleveland BioLabs own?

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the following people:
  • Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)
  • Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)
  • Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)
  • Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
  • Dr. Andrei Purmal Ph.D., VP of Chemistry

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $2.05.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $23.37 million and generates $1.11 million in revenue each year.

What is Cleveland BioLabs' official website?

The official website for Cleveland BioLabs is www.cbiolabs.com.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.